JP2012509265A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509265A5
JP2012509265A5 JP2011536403A JP2011536403A JP2012509265A5 JP 2012509265 A5 JP2012509265 A5 JP 2012509265A5 JP 2011536403 A JP2011536403 A JP 2011536403A JP 2011536403 A JP2011536403 A JP 2011536403A JP 2012509265 A5 JP2012509265 A5 JP 2012509265A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
hydrogen
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011536403A
Other languages
English (en)
Japanese (ja)
Other versions
JP5518088B2 (ja
JP2012509265A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/063696 external-priority patent/WO2010056620A1/en
Publication of JP2012509265A publication Critical patent/JP2012509265A/ja
Publication of JP2012509265A5 publication Critical patent/JP2012509265A5/ja
Application granted granted Critical
Publication of JP5518088B2 publication Critical patent/JP5518088B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011536403A 2008-11-17 2009-11-09 四置換ピリダジンヘッジホッグ経路アンタゴニスト Expired - Fee Related JP5518088B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11536208P 2008-11-17 2008-11-17
US61/115,362 2008-11-17
PCT/US2009/063696 WO2010056620A1 (en) 2008-11-17 2009-11-09 Tetrasubstituted pyridazines hedgehog pathway antagonists

Publications (3)

Publication Number Publication Date
JP2012509265A JP2012509265A (ja) 2012-04-19
JP2012509265A5 true JP2012509265A5 (enExample) 2012-12-27
JP5518088B2 JP5518088B2 (ja) 2014-06-11

Family

ID=41462228

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536403A Expired - Fee Related JP5518088B2 (ja) 2008-11-17 2009-11-09 四置換ピリダジンヘッジホッグ経路アンタゴニスト

Country Status (12)

Country Link
US (1) US8445493B2 (enExample)
EP (1) EP2358703B1 (enExample)
JP (1) JP5518088B2 (enExample)
KR (1) KR101335770B1 (enExample)
CN (1) CN102216292B (enExample)
AU (1) AU2009314288B2 (enExample)
BR (1) BRPI0921777A2 (enExample)
CA (1) CA2743264C (enExample)
EA (1) EA018372B1 (enExample)
ES (1) ES2446307T3 (enExample)
MX (1) MX2011005176A (enExample)
WO (1) WO2010056620A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981892B2 (en) 2008-04-29 2011-07-19 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
PE20110433A1 (es) 2008-11-03 2011-07-09 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida
PL2358698T3 (pl) 2008-11-17 2013-01-31 Lilly Co Eli Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
CN116349204A (zh) 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
ZA97288B (en) 1996-01-15 1998-07-14 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
CA2326654C (en) 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
ES2233383T3 (es) 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
AU2003231032B2 (en) * 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
KR20200019263A (ko) 2004-09-02 2020-02-21 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
EP2137162B1 (en) * 2007-03-15 2018-08-01 Novartis AG Organic compounds and their uses
ES2505091T3 (es) 2007-06-25 2014-10-09 Amgen Inc. Compuestos, composiciones y métodos de uso de ftalazina
US8222251B2 (en) 2007-09-07 2012-07-17 Amgen Inc. Pyridopyridazine compounds, compositions and methods of use
US7981892B2 (en) 2008-04-29 2011-07-19 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
PE20110433A1 (es) 2008-11-03 2011-07-09 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida
PL2358698T3 (pl) 2008-11-17 2013-01-31 Lilly Co Eli Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Similar Documents

Publication Publication Date Title
JP2012531433A5 (enExample)
JP2011527666A5 (enExample)
JP2014508811A5 (enExample)
JP2013537203A5 (enExample)
JP2010526814A5 (enExample)
JP2011037901A5 (enExample)
JP2017528475A5 (enExample)
JP2013525458A5 (enExample)
JP2011037841A5 (enExample)
JP2012507535A5 (enExample)
JP2016501882A5 (enExample)
JP2009535462A5 (enExample)
JP2014500870A5 (enExample)
JP2011509949A5 (enExample)
JP2010001302A5 (enExample)
JP2016503799A5 (enExample)
JP2017528467A5 (enExample)
JP2013510120A5 (enExample)
JP2012530705A5 (enExample)
JP2010504908A5 (enExample)
JP2015512943A5 (enExample)
JP2011513410A5 (enExample)
JP2010520214A5 (enExample)
JP2014508804A5 (enExample)
JP2012512863A5 (enExample)